Immix Biopharma
IMMX
8 hedge funds and large institutions have $352K invested in Immix Biopharma in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, 1 reducing their positions, and 9 closing their positions.
18.36% less ownership
Funds ownership: 20.3% → 1.93% (-18%)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
27% less funds holding
Funds holding: 11 → 8 (-3)
94% less capital invested
Capital invested by funds: $5.47M → $352K (-$5.12M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$232K |
| 2 |
VF
Virtu Financial
New York
|
+$87.3K |
| 3 |
ICG
InterOcean Capital Group
Nashville,
Tennessee
|
+$59K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$48.2K |
| 5 |
BlackRock
New York
|
+$35K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
M
Murchinson
Toronto,
Ontario, Canada
|
-$2.48M |
| 2 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
-$2.01M |
| 3 |
ACM
Altium Capital Management
New York
|
-$436K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$116K |
| 5 |
EVC
Eidelman Virant Capital
Saint Louis,
Missouri
|
-$103K |
IMMX Hedge Fund Activity: Q1 2022 in Review
8 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q1 2022, worth a combined $352K — down 94% from $5.47M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of IMMX and 7 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $232K. The largest seller was Murchinson, exiting entirely with an estimated $2.48M sold.
- 8 institutional investors held Immix Biopharma (IMMX) as of Q1 2022, down from 11 in Q4 2021.
- Funds reported $352K of Immix Biopharma stock for Q1 2022, down 94% quarter-over-quarter.
- 7 funds opened new Immix Biopharma positions in Q1 2022 and 9 closed out, a net change of -2 holders.
- The largest Immix Biopharma buyer in Q1 2022 was Renaissance Technologies, an estimated $232K added.
- The largest Immix Biopharma seller in Q1 2022 was Murchinson, an estimated $2.48M sold.
Based on aggregated 13F filings for Q1 2022.